TY - JOUR
T1 - Overcoming drug resistance in chronic myeloid leukemia
AU - Cortes, Jorge
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2006/3
Y1 - 2006/3
N2 - Purpose of review: Despite the excellent clinical results with imatinib in chronic myeloid leukemia, most patients have minimal residual disease and others will develop resistance and may eventually progress. Thus there is a need for developing approaches to overcome and prevent resistance to imatinib. Recent findings: Several new agents have been developed with significant activity in imatinib-resistant chronic myeloid leukemia. A second generation of more potent tyrosine kinase inhibitors, some with dual activity against Abl and Src, have shown very impressive results. Other agents, such as hypomethylating agents, farnesyl transferase inhibitors and homoharringtonine, have also shown preclinical and clinical promise. The use of vaccines as a way of providing an immunomodulatory approach to chronic myeloid leukemia is starting to develop as a major strategy to achieve eradication of the disease. Summary: Multiple effective agents are being developed to overcome resistance to imatinib. The challenge for the future is to incorporate them into effective strategies that can eliminate the disease and cure all patients with chronic myeloid leukemia.
AB - Purpose of review: Despite the excellent clinical results with imatinib in chronic myeloid leukemia, most patients have minimal residual disease and others will develop resistance and may eventually progress. Thus there is a need for developing approaches to overcome and prevent resistance to imatinib. Recent findings: Several new agents have been developed with significant activity in imatinib-resistant chronic myeloid leukemia. A second generation of more potent tyrosine kinase inhibitors, some with dual activity against Abl and Src, have shown very impressive results. Other agents, such as hypomethylating agents, farnesyl transferase inhibitors and homoharringtonine, have also shown preclinical and clinical promise. The use of vaccines as a way of providing an immunomodulatory approach to chronic myeloid leukemia is starting to develop as a major strategy to achieve eradication of the disease. Summary: Multiple effective agents are being developed to overcome resistance to imatinib. The challenge for the future is to incorporate them into effective strategies that can eliminate the disease and cure all patients with chronic myeloid leukemia.
KW - Chronic myeloid leukaemia
KW - Farnsyl transferase inhibitors
KW - Src inhibitors
KW - Tyrosine kinase inhibitors
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=33646806516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646806516&partnerID=8YFLogxK
U2 - 10.1097/01.moh.0000208468.40991.f2
DO - 10.1097/01.moh.0000208468.40991.f2
M3 - Review article
C2 - 16456373
AN - SCOPUS:33646806516
SN - 1065-6251
VL - 13
SP - 79
EP - 86
JO - Current Opinion in Hematology
JF - Current Opinion in Hematology
IS - 2
ER -